Investor Update

Basel, 10 May 2012

Roche conference call for investors and analysts from EULAR 2012

ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab
Friday, 8 June 2012, Berlin, Germany

We kindly invite investors and analysts to participate in a conference call that will be held during the EULAR Annual European Congress of Rheumatology from 6 - 9 June 2012 in Berlin.

On the call, Roche will discuss new data from ADACTA, the first study that was specifically designed to determine superiority between two approved biologic therapies for the treatment of rheumatoid arthritis in the monotherapy setting. The study evaluated if ACTEMRA (known as RoACTEMRA in Europe) was superior to adalimumab in reducing disease activity after 24 weeks in patients with severe active rheumatoid arthritis and intolerance or inadequate response to methotrexate.

Further, Roche will provide an update on development plans for the Actemra franchise. The presentation will be followed by a Q&A session.

The conference call will take place on:

Investors and analysts are invited to join the conference call either by live audio webcast or by telephone.

Live audio webcast

The live conference call can be accessed via http://ir.roche.com. Following the event, an MP3 file will be made available for download.

Phone conference call

The live conference call can be accessed using the following dial-in numbers:

Please dial in to the conference call 10 – 15 minutes before the call is scheduled to start.

A replay of the conference call will be available one hour after the conference call and then for 48 hours. The replay can be accessed using the following dial-in numbers:

Enter the ID 12079 followed by the # sign

At the time of the conference call, the accompanying presentation will be available from the IR website at http://ir.roche.com.